SEP363856
Total Payments
$13.4M
Transactions
1,440
Doctors
5
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $11.1M | 514 | 0 |
| 2017 | $2.3M | 926 | 5 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $13.4M | 1,440 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Clinical Trial to Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia | Sunovion Pharmaceuticals Inc. | $11.1M | 0 |
| A STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SEP-363856 IN ACUTELY PSYCHOTIC ADULTS WITH SCHIZOPHRENIA | Sunovion Pharmaceuticals Inc. | $1.9M | 3 |
| A STUDY TO EVALUATE THE EFFICACY, SAFETY AND TOLERABILITY OF SEP-363856 IN SUBJECTS WITH PARKINSON'S DISEASE PSYCHOSIS | Sunovion Pharmaceuticals Inc. | $199,519 | 2 |
| AN EXTENSION STUDY OF SAFETY AND TOLERABILITY OF SEP-363856 IN ADULT SUBJECTS WITH SCHIZOPHRENIA | Sunovion Pharmaceuticals Inc. | $148,854 | 0 |
| A Study of the Long-term Safety and Tolerability of an Investigational Drug in People With Schizophrenia. | Sunovion Pharmaceuticals Inc. | $3,585 | 0 |
| A Clinical Trial That Will Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia | Sunovion Pharmaceuticals Inc. | $1,681 | 0 |
| A Clinical Study to Evaluate the Long-term Safety and Tolerability of an Investigational Drug in People With Schizophrenia | Sunovion Pharmaceuticals Inc. | $12.50 | 0 |
Top Doctors Receiving Payments for SEP363856
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $13.4M
- Total Doctors 5
- Transactions 1,440
About SEP363856
SEP363856 is a drug associated with $13.4M in payments to 5 healthcare providers, recorded across 1,440 transactions in the CMS Open Payments database. The primary manufacturer is Sunovion Pharmaceuticals Inc..
Payment data is available from 2017 to 2020. In 2020, $11.1M was paid across 514 transactions to 0 doctors.
The most common payment nature for SEP363856 is "Unspecified" ($13.4M, 100.0% of total).
SEP363856 is associated with 7 research studies, including "A Clinical Trial to Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia" ($11.1M).